Cohen A T, Skinner J A, Kakkar V V
Thrombosis Research Institute, London.
BMJ. 1994 Nov 5;309(6963):1213-5. doi: 10.1136/bmj.309.6963.1213.
A recent meta-analysis from the Antiplatelet Trialists' Collaboration recommended that antilatelet treatment either alone or, for greater effect, in addition to other proved forms of thromboprophylaxis should be considered for patients at high risk of thromboembolism. This paper argues that the current evidence does not justify the adoption of aspirin or other antiplatelet treatment for venous thromboprophylaxis, especially when more effective alternatives exist. Furthermore, several issues relating to this latest meta-analysis need to be debated.
抗血小板试验协作组最近的一项荟萃分析建议,对于有血栓栓塞高风险的患者,应考虑单独使用抗血小板治疗,或者为了增强效果,在采用其他已证实的血栓预防方法的基础上再加用抗血小板治疗。本文认为,目前的证据并不支持采用阿司匹林或其他抗血小板治疗进行静脉血栓预防,尤其是在存在更有效替代方法的情况下。此外,与这项最新荟萃分析相关的几个问题有待探讨。